Veracyte (VCYT) said Monday a review article in Cancer Cytopathology, a journal of the American Cancer Society, describes how the technology behind...
Veracyte Inc. (VCYT) late Thursday said it plans to raise $127.9 million selling 5.5 million shares at $23.25 apiece, or 3.8% below Thursday's close....
Veracyte (VCYT) said it priced 5.5 million shares at $23.25 each in an underwritten public offering. The offering is expected to close on or about May 7....
Veracyte (VCYT) said it plans to sell 5 million shares in an underwritten public offering and expects to grant the underwriters a 30-day option to purchase...
| Address | 6000 Shoreline Court South San Francisco, California 94080 |
| Phone | +1.650.243.6300 |
| Number of Employees | 270 |
| Recent SEC Filing | 06/13/2019 4 |
| Chairman & Chief Executive Officer | Bonnie H. Anderson |
| President & Chief Operating Officer | Christopher M. Hall |
| Chief Financial Officer | Keith Kennedy |
| Chief Scientific & Medical Officer | Giulia C. Kennedy |
| Price Open | $28.82 |
| Previous Close | $28.33 |
| 52 Week Range | $8.77 - 29.38 |
| Market Capitalization | $1.2 B |
| Shares Outstanding | 41.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 07/22/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.42 |
| Beta vs. S&P 500 | N/A |
| Revenue | $92.0 M |
| Net Profit Margin | -15.51% |
| Return on Equity | -23.43% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
